Latest autoimmune diseases Stories

First Subject Enrolled in OPUS-2, SARcode Bioscience's Second Pivotal Study of Lifitegrast Ophthalmic Solution

2013-01-08 08:30:01

BRISBANE, Calif., Jan. 8, 2013 /PRNewswire/ -- SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial subject has been enrolled in a second pivotal Phase 3 clinical efficacy study (OPUS-2) of lifitegrast ophthalmic solution 5.0%. OPUS-2 will assess the efficacy and safety of lifitegrast in the treatment of dry eye disease. Approximately 700 subjects will be randomized to receive lifitegrast or placebo twice daily over 12 weeks....

Behcet’s Disease Has Genetic Link To Ancient Silk Road Trade Route

2013-01-07 10:42:03

Lawrence LeBlond for redOrbit.com - Your Universe Online Researchers continuing the study of the human genome have mapped out four new regions that are associated with a painful and often dangerous condition—Behcet’s disease—found in people with a lineage to ancestors along the Silk Road. The Silk Road was used as an important trade route for nearly 2,000 years, linking the Far East and Europe. But along with the trade of goods and cultures, also came the exchange of disease and...

Receptos Doses First Patient in Phase 2 Trial for RPC1063 in Ulcerative Colitis

2013-01-04 08:22:56

SAN DIEGO, Jan. 4, 2013 /PRNewswire/ -- Receptos, Inc., announced today that its selective sphingosine?1? phosphate 1 receptor (S1P1R) modulator, RPC1063, has been administered to the first patient in a Phase 2 study examining the clinical efficacy and safety of induction therapy in patients with moderately to severely active ulcerative colitis (UC). Leading to the initiation of the RPC01-202 study, called TOUCHSTONE, Receptos successfully filed an Investigational New Drug (IND)...

XBiotech Receives Fast Track Designation from FDA for True Human(TM) Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a for Restenosis

2013-01-03 16:23:17

AUSTIN, Texas, Jan. 3, 2013 /PRNewswire/ -- XBiotech, a privately held biotechnology company, announced today that the company has been granted Fast Track designation by the FDA for its therapeutic monoclonal antibody MABp1 (CV-18C3) as a treatment to reduce the need for re-intervention after superficial femoral artery (SFA) revascularization. Strong positive results from a recent Phase II study demonstrated that treatment with MABp1 resulted in prolonged patency of the SFA and...

Leading Dermatologist Michael P. Heffernan, M.D. and Renowned Rheumatologist Alisa E. Koch, M.D. Join Lilly Autoimmune Team

2013-01-03 12:24:48

INDIANAPOLIS, Jan. 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that Michael P. Heffernan, M.D., a nationally recognized expert in complex medical dermatology, psoriasis and clinical trials, has joined its autoimmune team as distinguished medical fellow. Alisa E. Koch, M.D., a rheumatologist who has won numerous academic awards for her extensive work in rheumatoid arthritis, joined as senior medical fellow. Most recently, Heffernan was in private practice at...

Questcor Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

2013-01-03 08:24:59

ANAHEIM, Calif., Jan. 3, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management is scheduled to present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 10, 2013 at 9:00 a.m. PT / 12:00 p.m. ET. A live webcast with accompanying slide presentation, and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay will be...

NGM Enters Agreement With Janssen to Discover and Develop Novel Therapeutics for Diabetes

2013-01-03 08:24:55

SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- NGM Biopharmaceuticals, Inc. announced today that it has signed a worldwide agreement with Janssen Pharmaceuticals, Inc. to discover and develop novel therapeutics for the potential treatment of Type 2 diabetes and other metabolic diseases. NGM and Janssen will jointly conduct research on selected protein factors discovered by NGM using its diabetes discovery platform, with the goal of advancing drug candidates that mimic...

Amakem Secures EUR1.4M Grant to Apply its Localized Drug Action Technology in Inflammatory Bowel Diseases (IBD)

2013-01-03 04:20:26

DIEPENBEEK, Belgium, January 3, 2013 /PRNewswire/ -- Amakem NV, a kinase platform company focusing on ophthalmology, today announces it has secured a EUR1.4M grant from the Flemish Agency for Innovation by Science and Technology (IWT), to apply its Localized Drug Action technology to the discovery and development of novel kinase inhibitor-based therapies for Inflammatory Bowel Diseases (IBD). IBD is a chronic, relapsing inflammatory disease of the gastrointestinal...

Autoimmune Treatment Market - New Industry Research Report is Now Available for Pre Order at Transparency Market Research

2013-01-02 05:04:34

A recently added market report by Transparency Market Research on “Autoimmune Treatment Market - Global Market Scenario, Trends, Industry Analysis And Forecast, 2012 - 2018" is now available for pre order. To Browse the report visit: http://www.transparencymarketresearch.com/autoimmune-treatment-market.html Albany, New York (PRWEB) December 31, 2012 Autoimmune diseases occur because of the body’s hyperactive immune response in relation to the tissues and substances normally...

Eye Scans Help Doctors Tell How Fast Multiple Sclerosis Progression Occurs

2012-12-26 11:04:46

Lawrence LeBlond for redOrbit.com - Your Universe Online Patients with debilitating multiple sclerosis may discover just how fast their nervous system disease is progressing with a new quick and easy test. The test, known as an Optical Coherence Tomography (OCT) scan, takes just a few minutes per eye and can be performed at a general practitioner’s surgery. The finding comes from a test of 164 MS patients measuring the thickness of the lining at the back of the eye. The test was...